No matches
Pulmonology

Compounded Burden of Co-existing Type 2 Airway Diseases

In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP​ & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.
Brian Lipworth
MD
Brian Lipworth

Related resources

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

expert video
Spotlight on Type 2 Inflammation in the Upper and Lower Airways

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

expert video
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

expert video
ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

expert video
IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

expert video
Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

expert video
What Are the Key Inflammatory Processes in Patients with COPD?

What Are the Key Inflammatory Processes in Patients with COPD?

expert video
ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD

ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD

expert video
ADVENT On Air | Many Faces of COPD: From Phenotypes to Endotypes

ADVENT On Air | Many Faces of COPD: From Phenotypes to Endotypes

Podcast
Pediatric Asthma Trajectory and Clinical Remission

Pediatric Asthma Trajectory and Clinical Remission

expert video
Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

expert video
ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

expert video
IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

expert video
How often do you suggest to assess sense of smell?

How often do you suggest to assess sense of smell?

expert video
Blood Eosinophils: A Biomarker in COPD

Blood Eosinophils: A Biomarker in COPD

Infographic
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction

expert video
Clinical Manifestations Associated With Airway Remodeling in Asthma

Clinical Manifestations Associated With Airway Remodeling in Asthma

expert video
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

videoanimation
Eosinophils as a Biomarker for Type 2 Asthma

Eosinophils as a Biomarker for Type 2 Asthma

expert video
ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

expert video
IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

expert video
What proportion of patients can achieve control in CRSwNP?

What proportion of patients can achieve control in CRSwNP?

expert video
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

expert video
ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

expert video
Pediatric Asthma Patient Case Tool: Ash

Pediatric Asthma Patient Case Tool: Ash

interactivity
GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

interactivity
Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

interactivity
EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

expert video
Dr. Giorgio Canonica Regarding Multidisciplinary Approach

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

expert video
ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

expert video
Role of Type 2 Cytokines in Asthma and COPD

Role of Type 2 Cytokines in Asthma and COPD

expert video
Adult Asthma Interactive Patient Cases

Adult Asthma Interactive Patient Cases

interactivity
CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

interactivity
Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Infographic
Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

videoanimation
Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

expert video
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Follow-Up

expert video
Exacerbations Lead to Worsening Lung Function

Exacerbations Lead to Worsening Lung Function

expert video
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

Infographic
CRSwNP: A Chronic Type 2 Inflammatory Disease

CRSwNP: A Chronic Type 2 Inflammatory Disease

expert video
ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

Podcast
Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

videoanimation
Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

interactivity
Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

expert video
ERS 2024 | Understanding the Complex Pathophysiology of COPD

ERS 2024 | Understanding the Complex Pathophysiology of COPD

expert video
Uncovering the Impact of Moderate COPD Exacerbations

Uncovering the Impact of Moderate COPD Exacerbations

interactivity
Partnering With Patients: Scores That Matter in CRSwNP

Partnering With Patients: Scores That Matter in CRSwNP

interactivity
ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Loss of Smell in CRSwNP Patients

Podcast
On-Treatment Clinical Remission in Asthma Patients Case Tool

On-Treatment Clinical Remission in Asthma Patients Case Tool

interactivity

Learning objectives

  • To understand the common type 2 pathophysiological mechanisms underlying severe asthma and CRSwNP and the compounded burden of co-existing type 2 inflammatory diseases
Tags
quality of lifeexpert insightssymposiumasthmaexacerbationscoexisting diseasesCRSwNP
MAT-GLB-2505225 - 1.0 - 09/2025

About this expert

Allergy/Immunology
Pulmonology

Brian Lipworth

MD

Brian Lipworth, MD, is a leading respiratory physician and researcher affiliated with Ninewells Hospital and Medical School, University of Dundee, Scotland, UK. His extensive body of work, reflected in highly cited publications, focuses on asthma and chronic obstructive pulmonary disease (COPD).

See author’s profile
Brian Lipworth

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: RomaniaChange country/region